Orphazyme
New therapies for the treatment of rare and genetic diseases.
Launch date
Employees
Market cap
$4.6m
Enterprise valuation
($2m) (Public information from Aug 2023)
Share price
DKK875 ORPH
Company register number 32266355
Copenhagen Capital Region of Denmark (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | <1m | 5.3m | 3.1m | 5.4m |
| % growth | - | - | - | - | 1700 % | (42 %) | 76 % |
| EBITDA | (19.1m) | (33.7m) | (49.0m) | (88.9m) | (83.9m) | (4.1m) | (1.8m) |
| % EBITDA margin | - | - | - | (30300 %) | (1589 %) | (133 %) | (33 %) |
| Profit | (18.5m) | (33.7m) | (49.4m) | (92.8m) | (92.0m) | 3.8m | (3.8m) |
| % profit margin | - | - | - | (31650 %) | (1742 %) | 124 % | (70 %) |
| EV / revenue | - | - | - | 836.0x | 14.9x | -0.5x | 0.8x |
| EV / EBITDA | -6.8x | -2.0x | -4.2x | -2.8x | -0.9x | 0.4x | -2.4x |
| R&D budget | - | - | 41.8m | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
$20.0m | Series A | ||
N/A | Grant | ||
$24.0m | Series B | ||
€14.0m | Late VC | ||
| N/A | €80.0m Valuation: €240m -30.0x EV/LTM EBITDA | IPO | |
* | N/A | $109m Valuation: $420m -8.6x EV/LTM EBITDA | Post IPO Equity |
* | $12.8m Valuation: $12.8m 2.4x EV/LTM Revenues | Acquisition | |
| Total Funding | $59.4m | ||
